Introducing PRISM by Chirasoph
Promising Advanced Therapy.
Investable Asset.
The execution liabilities aren’t always visible.
Change that with PRISM — Chemistry, Manufacturing & Controls risk, decoded early.
Technical and manufacturing complexities most often break promising cell & gene therapies (CGT), long before they reach clinical benchmarks. Much of this risk is assessable early, but it is easy to miss without the right lens. We help investors see it clearly, surfacing development and manufacturing risks before capital is committed.
THE PROBLEM
Most failures are
apparent — if you
know where to look.
Standard biopharma due diligence relies heavily on clinical data and scientific merit. Manufacturing readiness, capacity alignment, and supply chain resilience in advanced therapies are unique to them and they are where problems usually surface too late.
PRISM was built to change that.
PRISM focuses on the window where it matters most — where manufacturing risk is fully assessable, the decisions are still reversible.
88%
Phase I CGT attrition rate.
40%
Clinical halts in CGT linked to manufacturing and quality.
4x
Manufacturing & process delays in CGT compared to typical biologics.
THE TOOL
PRISM — Pipeline Risk Intelligence & Structured Mapping
Pipeline Risk Intelligence & Structured Mapping
01
Therapy Viability
Does the therapy’s design hold up outside the lab? We look at formulation stability, vector or construct design, and whether the underlying science is sound enough to carry into development.
02
Manufacturing Viability
Can this actually be made at scale, consistently? We assess scale-up risk in cell processing and lipid nanoparticle production, process economics along with quality testing readiness for later stages.
03
Capacity Readiness
Is there somewhere to make it? Clinical supply projections, CDMO capacity specific to advanced therapies, tech transfer readiness, especially for patient-specific manufacturing, where every batch is different.
04
Supply Assessment
Where do starting materials come from, and what happens if that source has a problem? We look at starting material sourcing, vendor qualification, single-source risk flags, geopolitical exposure, and backup supplier strategy.
WHO IT’s FOR
Built for the people
making high-stakes decisions
Investors
Due diligence teams
Rapidly assess technical risk in early stage portfolios guided through a structured framework that surfaces the questions that matter before capital is committed.
Biotech Leaders
Leadership teams
Understand the manufacturability and supply risks in your pipeline early — strengthening your investor narrative and bringing rigour to your go/no-go decisions.
BD & Licensing
External innovation
Evaluate in-licensing opportunities through a structured, expert-guided risk framework — before entering term sheets or committing to partnership negotiations.
FOUNDATION
“PRISM is built on direct experience and close working relationships across RNA/LNP delivery and cell and gene therapy manufacturing.”
METHOD
Trained on technical failure modes
Grounded in reported and direct development experience on critical bioprocessing failure modes — and designed to evolve as the data does.
PILLARS
Four evaluation dimensions
Each built around the decision points that determine whether a programme advances or stalls.
FOCUS
Built exclusively for ATMPs
For highest-leverage point of intervention — when course corrections are still possible and the cost of getting it right is a fraction of the cost of getting it wrong.
EARLY ACCESS
PRISM is coming.
Be among the first to use it.
We are currently working with a select group of partners — investors, founders, and BD teams — to bring it to life. If you’re evaluating or working on an advanced therapy asset and want to be among the first to access structured, expert-guided risk intelligence — register your interest below.
We will not share your details. No spam, ever.